HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bloom In US Demand For Immunity Supplements Prompts Abbott, Star Nutra And PRTCL Launches

Executive Summary

Abbott expands Pedialyte children’s line with adult products including Immune Support beverage in response to consumer demands for nutritional supplements to support immune health; Star Nutra introduces gummy immunity supplements; and PRTCL has a women’s immune-boost product.

You may also be interested in...



US Supplement Industry Rides Growth Amid Changes After Year Of Covid-19 Pandemic

“Many of those initial fears have abated as companies have learned more about transmission and how to protect staff,” says Tara Couch, EAS Consulting. But industry is changed and manufacturers are thinking more intently about supply chains and manufacturing processes.

Warnings Note Disease Treatment Studies Placed Too Close To Supplements For US FDA’s Comfort

Dietary ingredients identified in recent FDA warning letters as linked to disease claims by marketers directing customers to scientific literature include omega-3 fatty acid, ginkgo biloba, glucosamine curcumin and vitamin D.

Pandemic-Driven Trends Show Strong Immunity Supplement Future, Elderberry A Current 'Darling'

VMS, homeopathic and other natural producs firms couldn't plan for spike in demand from coronavirus 2019, but the pandemic provides information to continue riding heightened consumer interest to higher ongoing sales, researchers said in recent Council for Responsible Nutrition webinar.

Topics

Related Companies

UsernamePublicRestriction

Register

RS150961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel